Thomas A. Leedom
Isis Pharmaceuticals
10 Papers
89 Citations
Thomas A. Leedom is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Oligonucleotide & Nucleic acid. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism
Lynnetta Watts,Vara Prasad Manchem,Thomas A. Leedom,Amber L. Rivard,Robert Mckay,Dingjiu Bao,Teri Neroladakis,Brett P. Monia,Diane M. Bodenmiller,Julia Xiao-Chun Cao,Hong Yan Zhang,Amy L. Cox,Steven Jacobs,M. Dodson Michael,Kyle W. Sloop,Sanjay Bhanot +15 more
TL;DR: It is demonstrated that tissue-selective GCCR antagonism with ASOs may be a viable therapeutic strategy for the treatment of the metabolic syndrome and that GCCR ASO does not cause systemic GC antagonism.
140
Patent
Antisense oligonucleotides optimized for kidney targeting
Andrew M. Siwkowski,Edward Wancewicz,Thomas A. Leedom,Lynnetta Watts,Mausumee Guha,Brett P. Monia +5 more
- 21 Sep 2004
TL;DR: In this paper, an antisense oligonucleotide compound was proposed for targeting nucleic acid molecules expressed in the kidney, which was shown to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF).
56
Patent
Modulation of sglt2 expression
Susan M. Freier,Edward Wancewicz,Brett P. Monia,Andrew M. Siwkowski,Lynnetta Watts,Thomas A. Leedom +5 more
- 03 Nov 2004
TL;DR: In this paper, compositions of oligonucleotides, targeted to nucleic acid encoding SGLT2, are presented for modulation of the expression of SGLTs and methods for diagnosis and treatment of diseases and conditions associated with expression of sGLTs.
16
Patent
Backbone modifications to modulate oligonucleotide targeting in vivo
Andrew M. Siwkowski,Edward Wancewicz,Thomas A. Leedom,Lynnetta Watts,Mausumee Guha,Brett P. Monia,Richard H. Griffey,Richard S. Geary,Scott P. Henry,Arthur A. Levin +9 more
- 26 Feb 2007
TL;DR: In this paper, an antisense oligonucleotide compound optimized for targeting nucleic acid molecules expressed in the kidney was presented. But this compound was used to efficiently modulate the expression of target genes PTEN, SGLT2 and connective tissue growth factor (CTGF).
15
Patent
Modulation of sglt-2 expression
Susan M. Freier,Edward Wancewicz,Brett P. Monia,Andrew M. Siwkowski,Lynnetta Watts,Thomas A. Leedom +5 more
- 18 Nov 2011
TL;DR: In this article, compositions of oligonucleotides, targeted to nucleic acid encoding SGLT2, are presented for modulation of the expression of SGLTs and methods for diagnosis and treatment of diseases and conditions associated with expression of sGLTs.
2